T Cell Costimulatory Pathway Antibody Specificity and Ability to Activate Via A B 7 . 1-Antibody Fusion Protein

[1]  D. Oertli,et al.  Nonreplicating recombinant vaccinia virus encoding human B-7 molecules elicits effective costimulation of naive and memory CD4+ T lymphocytes in vitro. , 1997, Cellular immunology.

[2]  B. Gerstmayer,et al.  Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. , 1997, Journal of immunology.

[3]  Jing Ma,et al.  Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies , 1997, Nature Medicine.

[4]  G. Freeman,et al.  B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. , 1997, Journal of immunology.

[5]  S. Morrison,et al.  Design and production of novel tetravalent bispecific antibodies , 1997, Nature Biotechnology.

[6]  M. J. Coloma,et al.  Bifunctional fusion between nerve growth factor and a transferrin receptor antibody , 1997, Journal of neuroscience research.

[7]  J. Becker,et al.  Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. , 1996, The Journal of clinical investigation.

[8]  S. Morrison,et al.  In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. , 1996, Journal of immunology.

[9]  S. Morrison,et al.  An IgG3-IL-2 fusion protein has higher affinity than hrIL-2 for the IL-2R alpha subunit: real time measurement of ligand binding. , 1996, Molecular immunology.

[10]  J. Becker,et al.  An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. Moss,et al.  Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. , 1996, Cancer research.

[12]  J. Becker,et al.  T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy , 1996, The Journal of experimental medicine.

[13]  C. Uyttenhove,et al.  Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. , 1996, Journal of immunology.

[14]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Swain,et al.  The role of primary chemotherapy in early breast cancer. , 1996, Seminars in oncology.

[16]  E. Shpall,et al.  High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. , 1996, Seminars in oncology.

[17]  G. Sledge.  Adjuvant therapy for early stage breast cancer. , 1996, Seminars in oncology.

[18]  G. Freeman,et al.  B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. , 1996, Journal of immunology.

[19]  A. Seidman,et al.  Chemotherapy for advanced breast cancer: a current perspective. , 1996, Seminars in oncology.

[20]  T. Gajewski.  B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. , 1996, Journal of immunology.

[21]  W. L. Shupert,et al.  Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. , 1995, Cancer research.

[22]  J. Gribben,et al.  B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. , 1995, Immunity.

[23]  Y. Wu,et al.  Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain , 1995, The Journal of experimental medicine.

[24]  Laurie H Glimcher,et al.  B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy , 1995, Cell.

[25]  J. Gribben,et al.  Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. , 1994, Blood.

[26]  J. Schlom,et al.  Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. , 1994, Cancer research.

[27]  H. Sabzevari,et al.  A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Lieping Chen,et al.  Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. , 1994, Journal of immunology.

[29]  C. Döhring,et al.  T‐helper‐ and accessory‐cell‐independent cytotoxic responses to human tumor cells transfected with A B7 retroviral vector , 1994, International journal of cancer.

[30]  J. Johnston,et al.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity , 1994, The Journal of experimental medicine.

[31]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[32]  S. Morrison,et al.  Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. , 1992, Journal of immunological methods.

[33]  Brad Snedecor,et al.  High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment , 1992, Bio/Technology.

[34]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[35]  M. Campiglio,et al.  Selection of monoclonal antibodies which induce internalization and phosphorylation of P185HER2 and growth inhibition of cells with HER2/neu gene amplification , 1991, International journal of cancer.

[36]  P. Linsley,et al.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.

[37]  S. Morrison,et al.  Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Ullrich,et al.  Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues , 1990, International journal of cancer.

[39]  J. Bacus,et al.  HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. , 1990, Archives of pathology & laboratory medicine.

[40]  D. Slamon.  Proto-oncogenes and human cancers. , 1987, The New England journal of medicine.

[41]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[42]  L. Presta,et al.  Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. , 1995, Cancer research.

[43]  S. Morrison,et al.  In vitro antibodies: strategies for production and application. , 1992, Annual review of immunology.

[44]  A. Miller,et al.  Improved retroviral vectors for gene transfer and expression. , 1989, BioTechniques.